Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Oxion (88 likes)
- @polygon (77 likes)
[quote=“polygon, post:5276, topic:30365”]
- @fleksnes (73 likes)
Resten av topp 10:
-
@Bompiole (58 likes)
-
@Snoeffelen (55 likes)
-
@StockDZ (42 likes)
-
@Tjommien (41 likes)
-
@olafalo (40 likes)
-
@h3nk1 (37 likes)
-
@FiloD (33 likes)
Gratulerer!
1 Like
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @fleksnes (75 likes)
- @polygon (68 likes)
[quote=“polygon, post:5276, topic:30365”]
- @Oxion (67 likes)
Resten av topp 10:
-
@Snoeffelen (55 likes)
-
@olafalo (47 likes)
-
@Tjommien (46 likes)
-
@Bompiole (41 likes)
-
@h3nk1 (39 likes)
-
@nordpolen (31 likes)
-
@FiloD (30 likes)
Gratulerer!
Treatment of 3D In Vitro Tumoroids of Ovarian Cancer Using Photochemical Internalisation as a Drug Delivery Method by Layla Mohammad Hadi , Katerina Stamati , Elnaz Yaghini , Alexander J. MacRobert and Marilena Loizidou. Division of Surgery & Interventional Science, University College London. Biomedicines 2023, 11(2), 572; Received: 4 December 2022 / Revised: 5 February 2023 / Accepted: 5 February 2023 / Published: 15 February 2023. (This article belongs to the Special Issue 10th Anniversary of Biomedicines—3D In Vitro Models as an Alternative to Animal Experimentation: Advantages and Pitfalls) 4. Discussion. Ovarian cancer is one the deadliest cancers affecting women worldwide and often metastasises to the peritoneum causing the development of ascites. Treatment of ovarian cancer can be difficult as it is usually diagnosed late. The light-based treatments, PDT and PCI, have the potential to offer a non-invasive treatment for peritoneal carcinomatosis through the illumination of the peritoneal cavity. In this study, we used an in vitro 3D multicellular tumouroid model, to study the effect of PDT/PCI on ovarian cancer cells surrounded by a tumour microenvironment containing stromal cells, namely fibroblasts and endothelial cells. […] In our tumouroids, the HEY cancer cells were found to regrow and invade the stroma 7 days post-PDT treatment using TPPS2a (0.5 μg/mL) and 3 min of exposure to light (Figure 7B and Figure 8). According to the in vivo study by Schumann et al. (2015) [25] a single dose of combination therapy with the photosensitiser phthalocyanine (Pc) and siRNA as a DJ-1 gene suppressor led to a complete eradication of ovarian tumours (grown from A2780/AD cancer cells) without any evidence of recurrence in mice, whereas PDT only treated tumours began to regrow 16 days after treatment. They further explained that the ROS and heat generated after a single dose of PDT could initially produce a strong response in the tumours. They hypothesised that the further combination of the treatment with DJ-1 suppression resulted in a superior therapeutic effect, thus preventing tumour regrowth. In our in vitro study, we observed that a short time post-PDT treatment (48 h), cells within the central cancer mass diminished and cells invading the stroma were also reduced. However, incubation for an additional 5 days resulted in the regrowth of the cancer cells. This could suggest that a single dose of PDT can provide a strong response to begin with, but the cancer cells are eventually able to overcome the conditions produced by PDT as the treatment loses the effect if the additional cycles of the treatment are not provided. Since the oxygenation levels are likely to be higher at the edge of the cancer mass adjacent to the stroma than at the centre [18], we can postulate that PDT and PCI may elicit differential damage to the cells that invade the stroma compared to cells near the hypoxic core, but this would need further investigations. 5. Conclusions In this study we explored PCI efficacy in complex in vitro 3D tumouroids constructed using human ovarian cancer cells as a central mass and fibroblasts and endothelial cells as a surrounding stroma, using TPPS2a porphyrin as a photosensitiser and Saporin as a model cytotoxin. PCI was shown to be effective in tumouroids, causing damage to the central cancer mass and cells that had invaded the stroma, as well as the stroma-resident non-cancer cells. Using higher photosensitiser and light doses, PDT caused lethal damage to all three cell types within the complex tumouroids. A lower dose PDT treatment used as a comparison in the PCI experiment was shown to cause damage to both the central cancer mass as well as in the stroma for up to 2 days after light illumination. However, in a separate experiment, it was found that tumouroids that had undergone the same PDT treatment showed complete regrowth 7 days after exposure to light. Such an effect has also been observed in other PDT studies [25]. Overall, the results of our study are promising since our 3D tumouroid has the capability to better mimic in vivo tumour models and can be used for further cancer therapy studies, delineation of mechanisms for different cell types and the modelling of treatment regimens for full cancer tissue destruction.
1 Like
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @fleksnes (75 likes)
- @Oxion (67 likes)
- @polygon (59 likes)
Resten av topp 10:
-
@Snoeffelen (55 likes)
-
@olafalo (50 likes)
-
@Tjommien (46 likes)
-
@h3nk1 (39 likes)
-
@nordpolen (31 likes)
-
@Aaleby (30 likes)
-
@rockpus (23 likes)
Gratulerer!
1 Like
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Oxion (28 likes)
- @FiloD (19 likes)
- @olafalo (16 likes)
Resten av topp 10:
-
@StockDZ (12 likes)
-
@Chrkni (10 likes)
-
@Handyman (8 likes)
-
@Mitra (8 likes)
-
@Amatouren (8 likes)
-
@NJR (7 likes)
-
@Timm (6 likes)
Gratulerer!
https://soundcloud.com/user-972208711/episode-262
Hør dette intervju. Må da komme news snart.
Intervju er fra mars 2023.
3 Likes
Fundementale forhold. Ta det på småprat tråden
Innlevert patentsøknad for en ny type immunterapi. Forbedret resultatet, har cash ut mot slutten av 2024. Dette blir en spennende dag
5 Likes
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230512_2
Er ikke et PCIB som en kjenner til. Her har de faktisk snudd etter noen vanskelige år. Med noen positive testsvar i sommer Q2 så kan dette snu. 6-10 kr kan jo komme om vi er heldige.
Fra Q1 idag:
"The bioprocessing program for use of firmaNAc in gene therapy manufacturing has generated new results that add to the initial patent application filed in 2H 2022. Upcoming work will focus on generating results that can trigger testing with potential customers to get feedback and develop a competitive technology
6 Likes
Ny patentsøknad av Anders og Pål
Offentlig 04.05.2023
The present invention concerns a method of generating an immune response to bacteria in a subject, in which live bacteria (such as BCG) and a photosensitizing agent are administered to cells of the subject and the cells are irradiated with light of a wavelength effective to activate the photosensitizing agent to generate an immune response to the bacteria. Pharmaceutical compositions, products and kits for this purpose are also provided.
14 Likes
Spennende at PCIB skal delta på messe i USA.
BIO International 2023, Boston, US, 5-8 June 2023.
Hva kan vi forvente av PCIB fremover?
Har folk tro på den nye strategien til PCIB?
4 Likes